Hansa Biopharma AB
STO:HNSA
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| SE |
|
Hansa Biopharma AB
STO:HNSA
|
3.7B SEK |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
411.5B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
201.1B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
192.5B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.8B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.8B USD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.6B EUR |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
73.9B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -5 565 412.8% |
| 30th Percentile | -5.3% |
| Median | 3% |
| 70th Percentile | 7.5% |
| Max | 12 228% |
Other Profitability Ratios
Hansa Biopharma AB
Glance View
Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treats rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. The company is headquartered in Lund, Skane and currently employs 141 full-time employees. The company went IPO on 2007-10-17. The Company’s operations consist of research and development for drug discovery. The firm conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Hansa Biopharma AB is -238.1%, which is above its 3-year median of -447.1%.
Over the last 3 years, Hansa Biopharma AB’s Net Margin has increased from -395.5% to -238.1%. During this period, it reached a low of -747.9% on Sep 30, 2023 and a high of -238.1% on Jan 1, 2026.
